{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:11:15Z","timestamp":1771877475115,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ardea Biosciences, Inc."}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of the study was to evaluate the effect of lesinurad, a selective uric acid uptake inhibitor, alone and in combination with the xanthine oxidase inhibitor allopurinol, on serum uric acid and urinary urate excretion in patients with gout and hyperuricemia. A phase 1b, multicenter, open\u2010label, multiple\u2010dose study was carried out in patients with gout with serum uric acid\u00a0\u22658\u00a0mg\/dL following washout of urate\u2010lowering therapy. Patients were treated with allopurinol 300\u00a0mg\/day alone in week 1; lesinurad 400 or 600\u00a0mg\/day was added in week 2, followed by lesinurad 400 or 600\u00a0mg\/day alone in week 3. Serum uric acid and urine uric acid were evaluated each week. Safety was assessed throughout the study. Lesinurad 400 or 600\u00a0mg\/day added to allopurinol 300\u00a0mg\/day reduced serum uric acid by 60% and 72%, respectively, versus allopurinol alone (37%) or lesinurad 400\u00a0mg\/day (44%) or 600\u00a0mg\/day (47%) alone. A 100% response rate of serum uric acid\u00a0&lt;6\u00a0mg\/dL was achieved by all combinations (serum uric acid\u00a0&lt;5\u00a0mg\/dL by 50%\u201090%). Mean 24\u2010hour urate excretion compared with baseline was \u201335% with allopurinol, +36% and +56.5% with lesinurad 400\u00a0mg\/day and 600\u00a0mg\/day, respectively, and \u201311.6% and \u20137.1% with the respective combination therapies. Treatments were well tolerated. In this phase 1 trial, lesinurad added to allopurinol resulted in greater serum uric acid reduction than did allopurinol or lesinurad monotherapy.<\/jats:p>","DOI":"10.1002\/jcph.1124","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T15:46:14Z","timestamp":1525707974000},"page":"1164-1170","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout"],"prefix":"10.1002","volume":"58","author":[{"given":"Scott","family":"Baumgartner","sequence":"first","affiliation":[{"name":"drB Consulting Spokane WA USA"},{"name":"Ardea Biosciences, Inc. San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2010Tain","family":"Yeh","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc. San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zancong","family":"Shen","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc. San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Kerr","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc. San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Manhard","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc. San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Quart","sequence":"additional","affiliation":[{"name":"Ardea Biosciences, Inc. San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2012.11.2616"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-007-0001-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197906283002604"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4020"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61343-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000504"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2500"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature742"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000105320.04395.D0"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C800156200"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.11.001"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.106"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.005"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"issue":"11","key":"e_1_2_8_22_1","first-page":"2437","article-title":"The effect of control and self\u2010medication of chronic gout in a developing country. Outcome after 10 years","volume":"30","author":"Darmawan J","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23803"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23007"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091462"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket487"},{"issue":"12","key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1124\/dmd.105.006056","article-title":"Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone","volume":"33","author":"Iwanaga T","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840"},{"key":"e_1_2_8_32_1","unstructured":"Zurampic [package insert].Wilmington DE:AstraZeneca Pharmaceuticals LP;2015."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:49:35Z","timestamp":1751618975000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1002\/jcph.1124"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1124","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"assertion":[{"value":"2017-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}